Browsing by Author "Sundeep Kumar Goyal"

Now showing 1 - 2 of 2

Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus
(Indian Society of Gastroenterology, 2015) Jayant Kumar Ghosh; Sundeep Kumar Goyal; Vinod Kumar Dixit; A.K. Jain
[No abstract available]
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis
(Indian Society of Gastroenterology, 2015) Sundeep Kumar Goyal; Vinod Kumar Dixit; Suneet Kumar Shukla; Jayant Ghosh; Manas Behera; Manish Tripathi; Neha Gupta; Arttrika Ranjan; Ashok Kumar Jain
Background and Aims: Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with compensated or decompensated cirrhosis. Methods: We retrospectively analyzed laboratory and clinical data of 400 HBV-related cirrhotic patients without access to liver transplantation, who were treated with tenofovir/entecavir therapy, from January 2007 to January 2014. Two hundred and ten (52.5 %) patients had at least one of the components of decompensation at baseline. Two hundred and twenty (55 %) and 180 (45 %) patients were initiated tenofovir and entecavir, respectively. Follow up period was 45 (12–68) months for tenofovir and 36 (11–60) months for entecavir. Results: At the end of 1 year, levels of HBV DNA <20 IU/mL were achieved in 91.8 % and 88.8 % of patients, and alanine aminotransferase normalized in 54.5 % and 55.5 % of patients who received tenofovir and entecavir, respectively. At the last visit, Child-Turcotte-Pugh scores improved among 29.5 % of patients who received tenofovir, 25 % of those who received entecavir, and remained stable in 61.9 % and 65 % patients, respectively, in both groups. The 5-year cumulative rate of liver decompensation, hepatocellular carcinoma, and cirrhosis-related complications were 3.1 %, 1.9 %, and 2.1 % with an annual incidence of 0.8 %, 0.3 %, and 0.5 % per person-year, respectively. Conclusion: Tenofovir and entecavir were effective and potent drugs for prolonged treatment of HBV cirrhosis and improved the overall clinical course. © 2015, Indian Society of Gastroenterology.